Moderna D
D
MRNA
246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Moderna free cash flow 2016–2026What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
Moderna's free cash flow in Q3 FY2026, the three months to 30 September 2026, was -1.61B USD, against -880.00M USD on the same quarter a year before. Moderna's free cash flow in fiscal year 2025 was -2.07B USD, against -4.06B USD on the year before.
Last updated 6 Nov 2026 · Next report 12 Feb 2027
Free cash flow
Free cash flow Free cash flow margin
Growth
| Fiscal year | Period ending | Free cash flow | Growth | Free cash flow margin | Operating cash flow | Capital expenditure | Free cash flow per share |
|---|---|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -1.97B | — | -78.02% | -1.79B | -185.00M | -4.88 |
| FY2025 | 31 Dec 2025 | -2.07B | — | -106.22% | -1.87B | -192.00M | -5.31 |
| FY2024 | 31 Dec 2024 | -4.06B | — | -126.76% | -3.00B | -1.05B | -10.56 |
| FY2023 | 31 Dec 2023 | -3.83B | -183.50% | -55.86% | -3.12B | -707.00M | -10.01 |
| FY2022 | 31 Dec 2022 | 4.58B | -65.65% | 24.27% | 4.98B | -400.00M | 11.01 |
| FY2021 | 31 Dec 2021 | 13.34B | +580.57% | 75.19% | 13.62B | -284.00M | 30.94 |
| FY2020 | 31 Dec 2020 | 1.96B | — | 243.91% | 2.03B | -67.45M | 5.14 |
| FY2019 | 31 Dec 2019 | -490.52M | — | -814.70% | -458.97M | -31.55M | -1.48 |
| FY2018 | 31 Dec 2018 | -436.63M | — | -323.27% | -330.87M | -105.77M | -1.33 |
| FY2017 | 31 Dec 2017 | -389.89M | -1,260.72% | -189.43% | -331.48M | -58.40M | -1.04 |
| FY2016 | 31 Dec 2016 | 33.59M | — | 30.99% | 66.73M | -33.14M | 0.52 |
| Quarter | Period ending | Free cash flow | Growth on a year before | Free cash flow margin | Operating cash flow | Capital expenditure | Free cash flow per share |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | -1.61B | — | -122.32% | -1.56B | -47.00M | -3.73 |
| Q2 FY2026 | 30 Jun 2026 | -563.00M | — | -388.28% | -526.00M | -37.00M | -1.41 |
| Q1 FY2026 | 31 Mar 2026 | -692.00M | — | -177.89% | -630.00M | -62.00M | -1.75 |
| Q4 FY2025 | 31 Dec 2025 | 891.00M | +194.06% | 131.42% | 930.00M | -39.00M | 2.27 |
| Q3 FY2025 | 30 Sept 2025 | -880.00M | — | -86.61% | -847.00M | -33.00M | -2.26 |
| Q2 FY2025 | 30 Jun 2025 | -922.00M | — | -649.30% | -919.00M | -3.00M | -2.38 |
| Q1 FY2025 | 31 Mar 2025 | -1.16B | — | -1,087.85% | -1.04B | -127.00M | -3.02 |
| Q4 FY2024 | 31 Dec 2024 | 303.00M | -24.63% | 31.69% | 825.00M | -522.00M | 0.79 |
| Q3 FY2024 | 30 Sept 2024 | -1.72B | — | -92.56% | -1.57B | -151.00M | -4.30 |
| Q2 FY2024 | 30 Jun 2024 | -1.46B | — | -658.82% | -1.27B | -182.00M | -3.79 |
| Q1 FY2024 | 31 Mar 2024 | -1.19B | — | -709.58% | -989.00M | -196.00M | -3.10 |
| Q4 FY2023 | 31 Dec 2023 | 402.00M | -74.39% | 14.29% | 622.00M | -220.00M | 1.02 |
| Q3 FY2023 | 30 Sept 2023 | -1.74B | -1,167.48% | -95.03% | -1.60B | -140.00M | -4.57 |
| Q2 FY2023 | 30 Jun 2023 | -1.15B | -629.49% | -334.01% | -915.00M | -234.00M | -3.02 |
| Q1 FY2023 | 31 Mar 2023 | -1.34B | -150.86% | -72.80% | -1.23B | -113.00M | -3.30 |
| Q4 FY2022 | 31 Dec 2022 | 1.57B | -50.78% | 30.49% | 1.66B | -92.00M | 3.88 |
| Q3 FY2022 | 30 Sept 2022 | 163.00M | -94.87% | 5.06% | 252.00M | -89.00M | 0.40 |
| Q2 FY2022 | 30 Jun 2022 | 217.00M | -94.62% | 4.75% | 304.00M | -87.00M | 0.52 |
| Q1 FY2022 | 31 Mar 2022 | 2.63B | -10.39% | 44.29% | 2.76B | -132.00M | 6.18 |
| Q4 FY2021 | 31 Dec 2021 | 3.19B | +157.05% | 45.91% | 3.31B | -120.00M | 7.40 |
| Q3 FY2021 | 30 Sept 2021 | 3.18B | +263.73% | 65.79% | 3.28B | -99.00M | 7.32 |
| Q2 FY2021 | 30 Jun 2021 | 4.03B | — | 95.68% | 4.06B | -30.00M | 9.36 |
| Q1 FY2021 | 31 Mar 2021 | 2.94B | — | 168.45% | 2.97B | -35.00M | 6.83 |
| Q4 FY2020 | 31 Dec 2020 | 1.24B | — | 217.43% | 1.26B | -23.30M | 3.13 |
| Q3 FY2020 | 30 Sept 2020 | 873.46M | — | 553.14% | 892.75M | -19.29M | 2.21 |
| Q2 FY2020 | 30 Jun 2020 | -42.51M | — | -64.06% | -23.88M | -18.63M | -0.11 |
| Q1 FY2020 | 31 Mar 2020 | -112.41M | — | -1,340.02% | -106.19M | -6.22M | -0.32 |
| Q4 FY2019 | 31 Dec 2019 | -102.44M | — | -728.82% | -95.77M | -6.66M | -0.31 |
| Q3 FY2019 | 30 Sept 2019 | -113.76M | — | -667.36% | -107.05M | -6.71M | -0.34 |
| Q2 FY2019 | 30 Jun 2019 | -122.81M | — | -938.67% | -112.22M | -10.59M | -0.37 |
| Q1 FY2019 | 31 Mar 2019 | -151.52M | — | -945.54% | -143.93M | -7.60M | -0.46 |
| Q4 FY2018 | 31 Dec 2018 | -104.66M | — | -295.47% | -91.02M | -13.64M | -0.32 |
| Q3 FY2018 | 30 Sept 2018 | -106.35M | — | -254.69% | -80.21M | -26.14M | -0.33 |
| Q2 FY2018 | 30 Jun 2018 | -82.33M | — | -285.36% | -48.25M | -34.08M | -0.21 |
| Q1 FY2018 | 31 Mar 2018 | -143.29M | — | -493.45% | -111.39M | -31.91M | -0.36 |
| Q4 FY2017 | 31 Dec 2017 | -114.89M | — | -125.01% | -102.93M | -11.96M | -0.39 |
| Q3 FY2017 | 30 Sept 2017 | -71.72M | — | -168.86% | -42.62M | -29.10M | -1.11 |
| Q2 FY2017 | 30 Jun 2017 | -101.64M | — | -284.51% | -92.97M | -8.67M | -1.59 |
| Q1 FY2017 | 31 Mar 2017 | -101.64M | — | -284.51% | -92.97M | -8.67M | -1.59 |
Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow
Common questions about Moderna's free cash flow
Source: Financial Modeling Prep